Back to results
US 2023/0287083 A1Published application
Cd1 peptide-epitope for use in the treatment of a disease caused by an intracellular pathogen
AssigneeEqualy S.A.
InventorJean-Marie SAINT-REMY
Life of this patent
Estimating the term…
Abstract
A CD1 peptide-epitope for use in the treatment of a disease caused by an intracellular pathogen, the method for the identification of this CD1 peptide epitope, the pharmaceutical kit comprising this CD1 peptide epitope and the method to treat a patient against a disease caused by an intracellular pathogen or to prevent such infection, based on vaccination with this CD1 peptide-epitope.
Claims21
-14. (canceled)
A method of treating a disease, comprising:
- providing a CD1 peptide-epitope for use in the prevention or in the treatment of the disease, wherein the disease is caused by an intracellular pathogen, wherein the CD1 peptide-epitope is a fragment of a protein expressed by the intracellular pathogen, wherein:
- said CD1 peptide-epitope includes the sequence X1X2X3X4X5X6X7;
- said X2, X3, X4, X5, and X6 independently stand for any amino acid;
- and
- said X1 and X7 residues are independently F, W, T, H, or Y;
- administering the CD1 peptide-epitope to a subject having the disease;
- and
- administering at least one of:
- an inactivated form of the intracellular pathogen to the subject after administering the CD1 peptide-epitope;
- or
- a second peptide based on a protein of said intracellular pathogen to the subject after administering the CD1 peptide-epitope, said second peptide comprises the CD1 epitope-epitope and at least one MHC Class I epitope.
8 more elements
The method according to claim 1, wherein:
- said CD1 peptide-epitope is obtainable by an in vitro method for identifying one or several peptide-epitope(s) to activate NKT cells in a Th1-like and/or cytotoxic response towards an intracellular pathogen,
- said in vitro method comprises the steps of:
- identifying a CD1 peptide epitope in the said intracellular pathogen, and
- measuring in vitro the capacity of the identified CD1 peptide epitope to activate NKT cells in a Th1-like and/or cytotoxic response.
1 more element
A kit for use in the treatment of a disease caused by an intracellular pathogen comprising:
- a first peptide being a CD1 peptide-epitope, and
- a second peptide derived from said intracellular pathogen and being a peptide comprising said first peptide being the CD1 peptide-epitope in addition to other epitopes, wherein the CD1 peptide-epitope is a fragment of a protein expressed by the intracellular pathogen, wherein:
- said CD1 peptide-epitope includes the sequence X1X2X3X4X5X6X7;
- said X2, X3, X4, X5, and X6 independently stand for any amino acid;
- and
- said X1 and X7 residues are independently F, W, T, H, or Y.
3 more elements
Dependencies are inferred from the claim text.